Cimetidine Articles
GLOBAL DRUG MARKET: 30 YEARS OF GROWTH
4 January 1993
MERCK & CO EARNINGS ESTIMATES LOWERED
14 December 1992
GASTROINTESTINAL MARKET REVIEW
7 December 1992
EC COURT OVERTURNS UK DRUG PATENT RULING
9 November 1992
RPSGB CANDIDATES FOR POM-TO-P SWITCHING
2 November 1992
RX-TO-OTC SWITCHING FOR SUCCESS
2 November 1992
FOCUS ON IVAX PRODUCT PIPELINE
12 October 1992
ANTI-ULCER DRUG MARKET
5 October 1992
SIDE EFFECTS WITH OMEPRAZOLE?
7 September 1992
SB SETTLES JAPAN PATENT DISPUTE
3 August 1992
SK B injunction
6 July 1992
ZANTAC TOPS MAIL ORDER SALES IN USA
8 June 1992
FUJISAWA HIT BY JAPAN DRUG PRICING MOVES
1 June 1992
H PYLORI TREATMENT: A ROLE FOR OMEPRAZOLE?
25 May 1992
STUDY SUPPORTS ULCER/H PYLORI HYPOTHESIS
11 May 1992
THE UK DRUG INDUSTRYIN REVIEW: 1961-1991
4 May 1992
MOMENTUM OF 1991 CONTINUES AT SB
27 April 1992
EC PHARMA MARKET LURCHES TO COMPLETION
20 April 1992
POST-ELECTION OUTLOOK FOR UK HEALTH SECTOR
20 April 1992
MAINTENANCE ULCER THERAPY CUT URGED
6 April 1992
AUSTRALIAN LAUNCH OF ROCHE'S AURORIX
6 April 1992
AUSTRALIAN LAUNCH OF ROCHE'S AURORIX
6 April 1992
MAINTENANCE ULCER THERAPY CUT URGED
6 April 1992
US GENERIC DRUG MARKET TO 1995
17 February 1992
US OTC DRUGMAKERS A TAKEOVER TARGET
17 February 1992
STOCK MARKET COMMENTARY: EUROPE
10 February 1992
FIRST LAUNCH OF LANSOPRAZOLE
20 January 1992
APOTEK TO BUILD C$50M PHARMA UNIT
6 January 1992
ULCER DRUGS & ALCOHOL
6 January 1992
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
